Published on August 31, 2012 at 6:01 AM
Transition Therapeutics Inc. ("Transition" or the "Company") (TSX:TTH) (NASDAQ: TTHI) today announced that its licensing partner, Elan Corporation, plc
("Elan") has commenced a Phase 2, placebo-controlled, safety and
efficacy study of oral ELND005 as an adjunctive maintenance treatment
in patients with Bipolar I Disorder (BPD 1) to delay the time to
occurrence of mood episodes. As the first patient has been dosed in
this study, Transition will receive a milestone payment of US$ 11
million from Elan.
This bipolar clinical study is expected to enroll approximately 400
patients with BPD 1. Additional information on the study design and
protocol for this study ELND005-BPD201 can be found at http://clinicaltrials.gov/
Bipolar I Disorder (BPD) is a severe form of BPD, also commonly known as
manic depressive illness. It is a psychiatric disorder characterized
by excessive swings in a person's mood and energy affecting their
ability to function. BPD is a lifetime recurrent disorder with cycles
of dramatic mood swings of highs and lows, often with periods of normal
moods in between. The periods of highs and lows are called episodes of
mania and depression. BPD is also associated with increased
cardiovascular morbidity and suicide risk. The US and EU population of
BPD patients is estimated at approximately 3.5 million.
SOURCE Transition Therapeutics Inc.